Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina PharmaCAI:ISPH -1.45%82 5-Year Yield-on-Cost % is 1.01 as of Aug. 28, 2026, which is 25% below its 10-year median of 1.34. GuruFocus rates CAI:ISPH with a GF Score™ of 82/100 and a GF Value™ of E£11.62 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 69 Medical Distribution companies, Ibnsina Pharma ranks worse than 79.71% on this metric.
Ibnsina Pharma's yield on cost for the quarter that ended in Jun. 2026 was 1.01.
The historical rank and industry rank for Ibnsina Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:
CAI:ISPH'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.57 Med: 1.34 Max: 8.77
Current: 1.01
During the past 10 years, Ibnsina Pharma's highest Yield on Cost was 8.77. The lowest was 0.57. And the median was 1.34.
CAI:ISPH's 5-Year Yield-on-Cost % is ranked worse than 79.71% of 69
companies
in the Medical Distribution industry
Industry Median: 3.13
vs CAI:ISPH: 1.01
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Ibnsina Pharma 5-Year Yield-on-Cost % Related Terms
CAI:ISPH vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Ibnsina Pharma is calculated as
Ibnsina Pharma (CAI:ISPH) has a 5-Year Yield-on-Cost % of 1.01 as of Aug. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ibnsina Pharma and its competitors. This is 25% below median its historical median of 1.34. Over the past decade, Ibnsina Pharma's 5-Year Yield-on-Cost % has ranged from 0.57 to 8.77. According to the industry distribution chart, Ibnsina Pharma ranks #55 out of 69 companies in the Medical Distribution industry, placing it in the top 79.7%.
Is Ibnsina Pharma's 5-Year Yield-on-Cost % too high?
Ibnsina Pharma's current 5-Year Yield-on-Cost % of 1.01 is 25% below median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 8.77. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.13. Ibnsina Pharma's value of 1.01 is 67.7% below this industry median. Based on the distribution chart, Ibnsina Pharma ranks #55 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #55 out of 69 companies for 5-Year Yield-on-Cost %. This places Ibnsina Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.13. Ibnsina Pharma's value of 1.01 is 67.7% below this benchmark. Historically, Ibnsina Pharma's own 5-Year Yield-on-Cost % has ranged from 0.57 to 8.77 over the past decade. While the company's 10-year median is 1.34 vs. the industry median of 3.13, Ibnsina Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.13, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current 5-Year Yield-on-Cost % of 1.01 is 67.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current 5-Year Yield-on-Cost % is 1.01, which is 25% below median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£11.62, compared to a current price of E£12.92 — trading 11.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.01, which is 25% below median its 10-year median of 1.34 and 67.7% below the Medical Distribution industry median of 3.13. Ibnsina Pharma's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current 5-Year Yield-on-Cost % is 1.01 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£12.92 is trading 11.2% above its estimated GF Value™ of E£11.62.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
5-Year Yield-on-Cost %: 1.01 (25% below median its 10-year median of 1.34)
GF Value™: E£11.62 vs. price of E£12.92 (11.2% above fair value)
Industry Position: 67.7% below the Medical Distribution median (#55 of 69)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
82GF Score
Get the complete analysis for CAI:ISPH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
